Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Journey Medical (DERM) Shares Outstanding (Diluted Average) (2021 - 2025)

Historic Shares Outstanding (Diluted Average) for Journey Medical (DERM) over the last 5 years, with Q3 2025 value amounting to $25.0 million.

  • Journey Medical's Shares Outstanding (Diluted Average) rose 2152.77% to $25.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.0 million, marking a year-over-year increase of 2152.77%. This contributed to the annual value of $20.4 million for FY2024, which is 1206.08% up from last year.
  • As of Q3 2025, Journey Medical's Shares Outstanding (Diluted Average) stood at $25.0 million, which was up 2152.77% from $23.3 million recorded in Q2 2025.
  • Journey Medical's Shares Outstanding (Diluted Average)'s 5-year high stood at $25.0 million during Q3 2025, with a 5-year trough of $9.2 million in Q2 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Diluted Average) was $18.1 million (2023), whereas its average is $18.1 million.
  • In the last 5 years, Journey Medical's Shares Outstanding (Diluted Average) surged by 9230.9% in 2022 and then tumbled by 236.26% in 2024.
  • Over the past 5 years, Journey Medical's Shares Outstanding (Diluted Average) (Quarter) stood at $10.2 million in 2021, then surged by 72.05% to $17.5 million in 2022, then increased by 4.0% to $18.2 million in 2023, then rose by 12.06% to $20.4 million in 2024, then rose by 22.16% to $25.0 million in 2025.
  • Its last three reported values are $25.0 million in Q3 2025, $23.3 million for Q2 2025, and $22.6 million during Q1 2025.